Skip to main content
FDA OKs Iqirvo, First-in-Class PPAR Treatment for Primary Biliary Cholangitis
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
FDA OKs Iqirvo, First-in-Class PPAR Treatment for Primary Biliary Cholangitis
User login
Username
Password
Reset your password
Concept
Lead
score
Biliary Disease
1
1
Liver
0
0.62
Hepatic Fibrosis
0
0.53
Liver Disease
0
0.53
Cholangitis
0
0.99
Patient Safety
0
0.26
Adverse Effects
0
0.25
Cirrhosis
0
0.25
Pain Management
0
0.22
Abdominal Pain
0
0.21
Biliary Tract
0
0.17
Diarrhea
0
0.13
Weight Management
0
0.13
Abdomen
0
0.12
Bile
0
0.12
Cholestasis
0
0.12
Fatigue
0
0.12
Food and Drug Administration (FDA)
0
0.12
Grant
0
0.12
Nausea
0
0.12
Pain
0
0.12
Pruritus
0
0.12
Quality of Life
0
0.12
Receptors
0
0.12
Transplantation
0
0.12
Washington
0
0.12
Weight Gain
0
0.12
Specialty
Lead
score
Gastroenterology
1
1
Family Medicine/Primary Care
0
0.8
Internal Medicine
0
0.9
Pharmacist
0
0.7
Edit Tags